Avalon GloboCare Corp. (NASDAQ:ALBT) Short Interest Down 63.6% in January

Avalon GloboCare Corp. (NASDAQ:ALBT) was the target of a large decrease in short interest in the month of January. As of January 31st, there was short interest totalling 7,200 shares, a decrease of 63.6% from the January 15th total of 19,800 shares. Based on an average trading volume of 841,400 shares, the short-interest ratio is currently 0.0 days. Currently, 1.7% of the shares of the company are short sold.

Avalon GloboCare Price Performance

Shares of Avalon GloboCare stock opened at $3.69 on Friday. Avalon GloboCare has a 1 year low of $2.11 and a 1 year high of $21.60. The company has a market capitalization of $4.02 million, a price-to-earnings ratio of -0.18 and a beta of 0.19. The business has a fifty day simple moving average of $3.61 and a two-hundred day simple moving average of $3.60.

Avalon GloboCare (NASDAQ:ALBT) last announced its earnings results on Tuesday, November 12th. The company reported ($1.82) EPS for the quarter. The company had revenue of $0.35 million for the quarter.

About Avalon GloboCare

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells.